RxDoctor Payments Data

Lisa Berger, MD

Internal Medicine · New Hyde Park, NYNPI 1043325277

Payments from drug & device makers

$4,143in general payments, 2019–2025

Across 157 payments — averaging $26.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$417
  • AstraZeneca$327
  • Madrigal Pharmaceuticals$296
  • Amgen$222
  • OPKO Pharmaceuticals, LLC$169
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,05398%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,143 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$314,442
Medicare patients
739
Services billed
5,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate15$23,500
EliquisApixaban29$23,184
OzempicSemaglutide11$16,762
MounjaroTirzepatide16$16,579
Breo ElliptaFluticasone/Vilanterol22$13,408
SynthroidLevothyroxine Sodium123$9,280
Rosuvastatin Calcium404$5,547
Atorvastatin Calcium337$3,932
Candesartan Cilexetil48$3,654
Levothyroxine Sodium224$3,345
Escitalopram Oxalate204$3,206
Amlodipine Besylate365$2,543
Duloxetine Hcl53$2,440
Losartan Potassium152$1,941
Metoprolol Succinate102$1,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$23,18429 claims
Novo NordiskOzempic$1,074$16,76211 claims
Lilly USA, LLCMounjaro$417$16,57916 claims
GSKBreo Ellipta$106$13,40822 claims
AbbVieSynthroid$156$9,280123 claims
Almatica Pharma LLCSertraline Hcl$16$98788 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →